nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinonide—SMO—bone cancer	0.98	1	CbGaD
Fluocinonide—Telangiectasia—Methotrexate—bone cancer	0.000827	0.0686	CcSEcCtD
Fluocinonide—Secondary infection—Epirubicin—bone cancer	0.00062	0.0514	CcSEcCtD
Fluocinonide—Secondary infection—Doxorubicin—bone cancer	0.000574	0.0476	CcSEcCtD
Fluocinonide—NR3C1—Signaling events mediated by HDAC Class II—BCOR—bone cancer	0.000509	0.1	CbGpPWpGaD
Fluocinonide—Leukoderma—Methotrexate—bone cancer	0.000458	0.038	CcSEcCtD
Fluocinonide—SMO—GPCRs, Other—GRM1—bone cancer	0.000448	0.0879	CbGpPWpGaD
Fluocinonide—Infection—Carboplatin—bone cancer	0.000429	0.0356	CcSEcCtD
Fluocinonide—Leukoderma—Epirubicin—bone cancer	0.000429	0.0356	CcSEcCtD
Fluocinonide—Leukoderma—Doxorubicin—bone cancer	0.000397	0.0329	CcSEcCtD
Fluocinonide—Pain—Carboplatin—bone cancer	0.000369	0.0306	CcSEcCtD
Fluocinonide—Skin exfoliation—Cisplatin—bone cancer	0.000339	0.0281	CcSEcCtD
Fluocinonide—Eruption—Methotrexate—bone cancer	0.000317	0.0263	CcSEcCtD
Fluocinonide—Folliculitis—Methotrexate—bone cancer	0.00031	0.0257	CcSEcCtD
Fluocinonide—Budesonide—CYP3A4—bone cancer	0.000304	0.104	CrCbGaD
Fluocinonide—Fluticasone furoate—CYP3A4—bone cancer	0.000298	0.102	CrCbGaD
Fluocinonide—Eruption—Epirubicin—bone cancer	0.000296	0.0246	CcSEcCtD
Fluocinonide—Folliculitis—Epirubicin—bone cancer	0.00029	0.0241	CcSEcCtD
Fluocinonide—Nasal congestion—Cisplatin—bone cancer	0.000283	0.0235	CcSEcCtD
Fluocinonide—Eruption—Doxorubicin—bone cancer	0.000274	0.0227	CcSEcCtD
Fluocinonide—Folliculitis—Doxorubicin—bone cancer	0.000268	0.0223	CcSEcCtD
Fluocinonide—Flunisolide—CYP3A4—bone cancer	0.000255	0.0871	CrCbGaD
Fluocinonide—Paramethasone—CYP3A4—bone cancer	0.000252	0.086	CrCbGaD
Fluocinonide—Ciclesonide—CYP3A4—bone cancer	0.000248	0.0846	CrCbGaD
Fluocinonide—Fluorometholone—CYP3A4—bone cancer	0.000246	0.0839	CrCbGaD
Fluocinonide—NR3C1—Signaling events mediated by HDAC Class II—TUBB2A—bone cancer	0.000241	0.0473	CbGpPWpGaD
Fluocinonide—Methylprednisolone—CYP3A4—bone cancer	0.000238	0.0811	CrCbGaD
Fluocinonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—ATF1—bone cancer	0.000237	0.0466	CbGpPWpGaD
Fluocinonide—Nasopharyngitis—Cisplatin—bone cancer	0.00023	0.0191	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptors—NR1I2—bone cancer	0.000228	0.0447	CbGpPWpGaD
Fluocinonide—Glycosuria—Epirubicin—bone cancer	0.000225	0.0187	CcSEcCtD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—FEV—bone cancer	0.000217	0.0426	CbGpPWpGaD
Fluocinonide—Glycosuria—Doxorubicin—bone cancer	0.000208	0.0173	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000205	0.0402	CbGpPWpGaD
Fluocinonide—Triamcinolone—CYP3A4—bone cancer	0.000201	0.0684	CrCbGaD
Fluocinonide—Triamcinolone—PTGS2—bone cancer	0.000196	0.067	CrCbGaD
Fluocinonide—Skin exfoliation—Methotrexate—bone cancer	0.000186	0.0154	CcSEcCtD
Fluocinonide—Dermatitis contact—Epirubicin—bone cancer	0.00018	0.0149	CcSEcCtD
Fluocinonide—NR3C1—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00018	0.0353	CbGpPWpGaD
Fluocinonide—Fluticasone Propionate—CYP3A4—bone cancer	0.000179	0.0611	CrCbGaD
Fluocinonide—Skin exfoliation—Epirubicin—bone cancer	0.000174	0.0144	CcSEcCtD
Fluocinonide—Dermatitis contact—Doxorubicin—bone cancer	0.000167	0.0138	CcSEcCtD
Fluocinonide—Betamethasone—CYP3A4—bone cancer	0.000164	0.056	CrCbGaD
Fluocinonide—Skin exfoliation—Doxorubicin—bone cancer	0.000161	0.0134	CcSEcCtD
Fluocinonide—Immune system disorder—Cisplatin—bone cancer	0.000161	0.0134	CcSEcCtD
Fluocinonide—Betamethasone—PTGS2—bone cancer	0.000161	0.0548	CrCbGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000159	0.0312	CbGpPWpGaD
Fluocinonide—Erythema—Cisplatin—bone cancer	0.000155	0.0129	CcSEcCtD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—EGFR—bone cancer	0.000153	0.0299	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—GRM4—bone cancer	0.000146	0.0287	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000145	0.0284	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000143	0.028	CbGpPWpGaD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000131	0.0109	CcSEcCtD
Fluocinonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—bone cancer	0.000127	0.0249	CbGpPWpGaD
Fluocinonide—SMO—GPCR ligand binding—GRM1—bone cancer	0.000127	0.0249	CbGpPWpGaD
Fluocinonide—Infection—Cisplatin—bone cancer	0.000126	0.0104	CcSEcCtD
Fluocinonide—Nervous system disorder—Cisplatin—bone cancer	0.000124	0.0103	CcSEcCtD
Fluocinonide—Skin disorder—Cisplatin—bone cancer	0.000123	0.0102	CcSEcCtD
Fluocinonide—Dry skin—Epirubicin—bone cancer	0.000121	0.0101	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000121	0.0237	CbGpPWpGaD
Fluocinonide—Nasopharyngitis—Epirubicin—bone cancer	0.000118	0.00981	CcSEcCtD
Fluocinonide—Dry skin—Doxorubicin—bone cancer	0.000112	0.00931	CcSEcCtD
Fluocinonide—Nasopharyngitis—Doxorubicin—bone cancer	0.00011	0.00908	CcSEcCtD
Fluocinonide—Pain—Cisplatin—bone cancer	0.000108	0.00898	CcSEcCtD
Fluocinonide—Hyperglycaemia—Epirubicin—bone cancer	0.000103	0.00856	CcSEcCtD
Fluocinonide—Dexamethasone—CYP3A4—bone cancer	9.55e-05	0.0326	CrCbGaD
Fluocinonide—Hyperglycaemia—Doxorubicin—bone cancer	9.55e-05	0.00792	CcSEcCtD
Fluocinonide—Dexamethasone—PTGS2—bone cancer	9.35e-05	0.0319	CrCbGaD
Fluocinonide—Hypersensitivity—Cisplatin—bone cancer	9.33e-05	0.00774	CcSEcCtD
Fluocinonide—NR3C1—Generic Transcription Pathway—ZNF77—bone cancer	9.18e-05	0.018	CbGpPWpGaD
Fluocinonide—NR3C1—Endoderm Differentiation—EZH2—bone cancer	9.17e-05	0.018	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	8.96e-05	0.0176	CbGpPWpGaD
Fluocinonide—Immune system disorder—Methotrexate—bone cancer	8.84e-05	0.00733	CcSEcCtD
Fluocinonide—Erythema—Methotrexate—bone cancer	8.52e-05	0.00706	CcSEcCtD
Fluocinonide—Immune system disorder—Epirubicin—bone cancer	8.27e-05	0.00686	CcSEcCtD
Fluocinonide—Rash—Cisplatin—bone cancer	7.99e-05	0.00662	CcSEcCtD
Fluocinonide—Dermatitis—Cisplatin—bone cancer	7.98e-05	0.00662	CcSEcCtD
Fluocinonide—Erythema—Epirubicin—bone cancer	7.97e-05	0.00661	CcSEcCtD
Fluocinonide—Immune system disorder—Doxorubicin—bone cancer	7.65e-05	0.00635	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—RGS1—bone cancer	7.51e-05	0.0147	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—GRM4—bone cancer	7.51e-05	0.0147	CbGpPWpGaD
Fluocinonide—Erythema—Doxorubicin—bone cancer	7.38e-05	0.00612	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	7.2e-05	0.00597	CcSEcCtD
Fluocinonide—Infection—Methotrexate—bone cancer	6.91e-05	0.00573	CcSEcCtD
Fluocinonide—Nervous system disorder—Methotrexate—bone cancer	6.82e-05	0.00565	CcSEcCtD
Fluocinonide—Skin disorder—Methotrexate—bone cancer	6.75e-05	0.0056	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	6.74e-05	0.00559	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	6.65e-05	0.013	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—GRM1—bone cancer	6.51e-05	0.0128	CbGpPWpGaD
Fluocinonide—Infection—Epirubicin—bone cancer	6.46e-05	0.00536	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	6.41e-05	0.0126	CbGpPWpGaD
Fluocinonide—Nervous system disorder—Epirubicin—bone cancer	6.38e-05	0.00529	CcSEcCtD
Fluocinonide—Skin disorder—Epirubicin—bone cancer	6.32e-05	0.00524	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	6.24e-05	0.00517	CcSEcCtD
Fluocinonide—Infection—Doxorubicin—bone cancer	5.98e-05	0.00496	CcSEcCtD
Fluocinonide—Pain—Methotrexate—bone cancer	5.95e-05	0.00493	CcSEcCtD
Fluocinonide—Nervous system disorder—Doxorubicin—bone cancer	5.9e-05	0.00489	CcSEcCtD
Fluocinonide—Skin disorder—Doxorubicin—bone cancer	5.85e-05	0.00485	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	5.78e-05	0.0113	CbGpPWpGaD
Fluocinonide—Pain—Epirubicin—bone cancer	5.56e-05	0.00461	CcSEcCtD
Fluocinonide—NR3C1—AP-1 transcription factor network—PLAU—bone cancer	5.35e-05	0.0105	CbGpPWpGaD
Fluocinonide—Pain—Doxorubicin—bone cancer	5.15e-05	0.00427	CcSEcCtD
Fluocinonide—Hypersensitivity—Methotrexate—bone cancer	5.12e-05	0.00425	CcSEcCtD
Fluocinonide—Pruritus—Methotrexate—bone cancer	4.92e-05	0.00408	CcSEcCtD
Fluocinonide—Hypersensitivity—Epirubicin—bone cancer	4.79e-05	0.00397	CcSEcCtD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—MDM2—bone cancer	4.68e-05	0.00919	CbGpPWpGaD
Fluocinonide—Pruritus—Epirubicin—bone cancer	4.6e-05	0.00382	CcSEcCtD
Fluocinonide—Dizziness—Methotrexate—bone cancer	4.6e-05	0.00381	CcSEcCtD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.54e-05	0.00891	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	4.5e-05	0.00883	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—GRM4—bone cancer	4.44e-05	0.00871	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—RGS1—bone cancer	4.44e-05	0.00871	CbGpPWpGaD
Fluocinonide—Hypersensitivity—Doxorubicin—bone cancer	4.44e-05	0.00368	CcSEcCtD
Fluocinonide—NR3C1—Gene Expression—ZNF77—bone cancer	4.42e-05	0.00867	CbGpPWpGaD
Fluocinonide—Rash—Methotrexate—bone cancer	4.38e-05	0.00363	CcSEcCtD
Fluocinonide—Dermatitis—Methotrexate—bone cancer	4.38e-05	0.00363	CcSEcCtD
Fluocinonide—Headache—Methotrexate—bone cancer	4.36e-05	0.00361	CcSEcCtD
Fluocinonide—Dizziness—Epirubicin—bone cancer	4.3e-05	0.00357	CcSEcCtD
Fluocinonide—Pruritus—Doxorubicin—bone cancer	4.26e-05	0.00353	CcSEcCtD
Fluocinonide—SMO—Signaling by GPCR—GNA11—bone cancer	4.2e-05	0.00824	CbGpPWpGaD
Fluocinonide—Rash—Epirubicin—bone cancer	4.1e-05	0.0034	CcSEcCtD
Fluocinonide—Dermatitis—Epirubicin—bone cancer	4.1e-05	0.0034	CcSEcCtD
Fluocinonide—Headache—Epirubicin—bone cancer	4.08e-05	0.00338	CcSEcCtD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—JUN—bone cancer	4.07e-05	0.00799	CbGpPWpGaD
Fluocinonide—Dizziness—Doxorubicin—bone cancer	3.98e-05	0.0033	CcSEcCtD
Fluocinonide—SMO—Signaling Pathways—GRM1—bone cancer	3.85e-05	0.00755	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.81e-05	0.00748	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—IL3—bone cancer	3.81e-05	0.00747	CbGpPWpGaD
Fluocinonide—Rash—Doxorubicin—bone cancer	3.8e-05	0.00315	CcSEcCtD
Fluocinonide—Dermatitis—Doxorubicin—bone cancer	3.79e-05	0.00314	CcSEcCtD
Fluocinonide—Headache—Doxorubicin—bone cancer	3.77e-05	0.00313	CcSEcCtD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—MDM2—bone cancer	3.3e-05	0.00648	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—JUN—bone cancer	3.26e-05	0.00639	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—MMP9—bone cancer	3.17e-05	0.00622	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—NR1I2—bone cancer	3.11e-05	0.00609	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	2.9e-05	0.00569	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—JUN—bone cancer	2.87e-05	0.00563	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—RB1—bone cancer	2.68e-05	0.00526	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—GNA11—bone cancer	2.48e-05	0.00487	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—ATF1—bone cancer	2.31e-05	0.00452	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IL3—bone cancer	2.25e-05	0.00441	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—FUS—bone cancer	2.16e-05	0.00423	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—TP53—bone cancer	2.15e-05	0.00422	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TGFBR2—bone cancer	1.92e-05	0.00377	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—bone cancer	1.89e-05	0.00372	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IGF1R—bone cancer	1.81e-05	0.00355	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—JUN—bone cancer	1.72e-05	0.00337	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—NR1I2—bone cancer	1.5e-05	0.00293	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—KIT—bone cancer	1.31e-05	0.00257	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—BRAF—bone cancer	1.23e-05	0.00242	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—EGFR—bone cancer	1.2e-05	0.00235	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—EIF2S1—bone cancer	1.1e-05	0.00217	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MDM2—bone cancer	1.03e-05	0.00203	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—EZH2—bone cancer	9.59e-06	0.00188	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—JUN—bone cancer	8.98e-06	0.00176	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MMP9—bone cancer	8.74e-06	0.00171	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—EGFR—bone cancer	7.06e-06	0.00139	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TP53—bone cancer	5.93e-06	0.00116	CbGpPWpGaD
